Alopecia Areata Market Poised For Growth Through 2036, Driven By Rising Diagnosis Rates And Breakthrough Targeted Therapies

(MENAFN- GlobeNewsWire - Nasdaq) Limited JAK-only options, safety concerns and access barriers create opportunities for safer, affordable therapies with novel immune targets and durable hair regrowth.

Dublin, Sept. 17, 2026 (GLOBE NEWSWIRE) -- "Alopecia Areata - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The alopecia areata market across the seven major markets-the United States, Germany, France, Italy, Spain, the United Kingdom and Japan-was valued at approximately USD 850 million in 2025. The market is projected to grow at a compound annual growth rate of 24.4% from 2022 to 2036, supported by increasing diagnosis, greater treatment adoption, new product launches and continued development of therapies targeting immune pathways beyond established approaches.

The "Alopecia Areata - Market Insights, Epidemiology, and Market Forecast - 2036" report provides an in-depth assessment of historical and forecast epidemiology, treatment practices, market size, therapy uptake, competitive dynamics and commercial opportunities across the seven major markets. It also examines patient burden, market access, reimbursement, pricing trends, unmet needs and the clinical development pipeline.

Key Alopecia Areata Market Insights

• The alopecia areata market in the seven major markets reached approximately USD 850 million in 2025.
• The United States represented the largest regional market, generating approximately USD 500 million in 2025.
• EU4 and the United Kingdom collectively generated approximately USD 300 million, while Japan accounted for approximately USD 60 million.
• The United States recorded approximately 800,000 prevalent cases and around 630,000 diagnosed prevalent cases in 2025.
• The United Kingdom had the highest diagnosed prevalence among EU4 and the UK, with approximately 330,000 cases in 2025.
• Females represented approximately 63% of alopecia areata cases in EU4 and the UK, compared with 37% among males.
• Approximately 14% of cases in EU4 and the UK were categorized as mild, 45% as moderate and 41% as severe.

Current Alopecia Areata Treatment Landscape

The alopecia areata treatment market has changed substantially following the introduction of targeted oral therapies. Three US FDA-approved JAK inhibitors currently anchor the approved treatment landscape: OLUMIANT, developed by Eli Lilly and Company and Incyte Corporation; LITFULO, developed by Pfizer; and LEQSELVI, developed by Sun Pharmaceutical Industries.

OLUMIANT became the first JAK inhibitor approved for alopecia areata in 2022. LITFULO followed in 2023 and expanded targeted treatment availability to eligible adolescent patients. LEQSELVI received US FDA approval in July 2024 for adults with severe alopecia areata and entered the US market in 2025 after the resolution of patent-related launch restrictions.

Despite these advances, reliance on one therapeutic class limits treatment diversity. JAK inhibitors are associated with safety considerations that may include serious infections, malignancies, major cardiovascular events, thrombosis and laboratory abnormalities. These risks can affect long-term utilization, prescribing decisions and patient acceptance, particularly in chronic treatment settings.

Corticosteroids, topical immunotherapy, minoxidil, anthralin and systemic immunosuppressive agents continue to be used according to disease severity and prior response. However, inconsistent efficacy, relapse after treatment discontinuation and treatment-related adverse events reinforce the need for therapies capable of delivering sustained hair regrowth with improved long-term safety.

Emerging Alopecia Areata Therapies and Pipeline

The alopecia areata pipeline includes candidates designed to improve immune regulation, restore tolerance and produce more durable clinical outcomes. Leading programs include upadacitinib, Coacillium, rezpegaldesleukin and STS-01.

AbbVie is evaluating upadacitinib, marketed as RINVOQ in approved indications, in Phase III development for severe alopecia areata. The company reported positive topline findings from its second Phase III UP-AA study in August 2025. Regulatory decisions for the alopecia areata indication are anticipated around 2027, while the broader clinical program is expected to continue through 2028.

Legacy Healthcare plans to advance Coacillium, also known as LH-8, into an international Phase III study following US FDA clearance reported in January 2026. Soterios Pharma's STS-01 has completed Phase II development in mild-to-moderate alopecia areata. Results reported in May 2024 indicated that the topical, non-steroidal candidate was well tolerated, with no significant adverse events identified.

These emerging therapies could broaden the competitive landscape by offering alternative mechanisms, formulations and routes of administration. Their future commercial performance will depend on clinical efficacy, durability, safety, pricing, reimbursement, physician adoption and the size of the addressable patient population.

Alopecia Areata Epidemiology and Patient Burden

Prevalence and diagnosed prevalence are expected to rise across the seven major markets through 2036. In 2025, the United States accounted for the largest prevalent population, with approximately 800,000 cases. Among EU4 and the United Kingdom, the UK recorded approximately 330,000 diagnosed prevalent cases, followed by Spain with around 180,000. Italy had the lowest diagnosed prevalence in this group, at nearly 100,000 cases.

Japan recorded approximately 170,000 diagnosed prevalent cases among females and nearly 110,000 among males in 2025. Across the covered markets, differences in diagnosis, disease severity, treatment eligibility and access to specialist care will remain important determinants of therapy adoption and revenue growth.

Market Access, Pricing and Reimbursement

High treatment costs and uneven access remain major barriers within the alopecia areata therapeutics market. OLUMIANT has an estimated annual treatment cost of approximately USD 30,000 in the United States, illustrating the affordability challenges associated with long-term targeted therapy.

Reimbursement decisions will continue to depend on the relationship between treatment cost and demonstrated clinical benefit. Payers and other healthcare stakeholders are evaluating access programs and alternative payment approaches to reduce the financial burden associated with high-cost therapies. Pricing strategies for emerging products will directly influence patient access, treatment adherence, market penetration and peak sales potential.

Competitive Landscape and Leading Companies

Major companies shaping the alopecia areata market include Eli Lilly and Company, Incyte Corporation, Pfizer, Sun Pharmaceutical Industries, AbbVie, Legacy Healthcare and Nektar Therapeutics. Competition is expected to intensify as late-stage products approach regulatory review and companies seek differentiation through efficacy, safety, dosing convenience, route of administration and broader patient eligibility.

The report evaluates approved and pipeline therapies across Phase I-III development, including clinical data, regulatory status, patents, collaborations, strategic partnerships and upcoming catalysts. It also assesses therapy uptake, peak patient share, sales potential and the principal factors expected to affect product performance through 2036.

Unmet Needs and Market Opportunities

• More durable hair regrowth and reduced relapse rates
• Additional therapeutic classes beyond JAK inhibition
• Improved options for patients with severe, refractory or chronic disease
• Favorable long-term safety profiles
• Earlier diagnosis and greater disease awareness
• Improved affordability, reimbursement and geographic access
• Stronger evidence supporting treatment sequencing and switching decisions

Report Scope and Strategic Value

The report includes an 11-year alopecia areata market forecast, epidemiology-based bottom-up modeling, patient population projections, treatment addressable market analysis, drug uptake forecasts, competitive intelligence and country-level market assessments. Qualitative analysis includes SWOT and attribute-based evaluations of emerging therapies according to efficacy, safety, administration frequency, route of administration, order of entry, probability of success and addressable patient pool.

Insights from more than eight key opinion leaders and subject-matter experts support the analysis of real-world prescribing, patient adherence, therapy switching, clinical practice, market access and unmet medical needs. These findings can assist pharmaceutical companies, investors, healthcare providers and other stakeholders in refining clinical development, commercialization, market-entry and portfolio strategies.

The projected expansion of the alopecia areata market reflects a combination of substantial patient need, improving diagnosis and rapid therapeutic innovation. Although approved JAK inhibitors have established a targeted treatment category, opportunities remain for differentiated therapies that can deliver sustained efficacy, improved safety, accessible pricing and broader patient coverage through 2036.

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Alopecia Areata Market Overview at a Glance
3.1. Market Share (%) Distribution of Alopecia Areata by Therapies in the 7MM in 2025
3.2. Market Share (%) Distribution of Alopecia Areata by Therapies in the 7MM in 2036
4. Executive Summary
5. Key Events
6. Disease Background and Overview
6.1. Introduction
6.2. Clinical Manifestation
6.3. Risk Factors
6.4. Prognosis
6.5. Diagnosis
6.5.1. Diagnostic Guidelines
6.5.2. Differential diagnosis
6.6. Treatment
6.6.1. Treatment Guidelines
6.6.2. Treatment Algorithm
7. Epidemiology and Market Methodology
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: 7MM
8.2.1. Prevalent Cases of Alopecia Areata
8.2.2. Diagnosed Prevalent Cases of Alopecia Areata
8.2.3. Gender-specific Diagnosed Prevalent Cases of Alopecia Areata
8.2.4. Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata
8.2.5. Severity-specific Diagnosed Prevalent Cases of alopecia areata
8.3. Diagnosed Prevalent Cases of Alopecia Areata in the 7MM
8.4. The United States
8.4.1. Prevalent Cases of Alopecia Areata in the US
8.4.2. Diagnosed Prevalent Cases of Alopecia Areata in the US
8.4.3. Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in the US
8.4.4. Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in the US
8.4.5. Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in the US
8.5. EU4 and the UK
8.5.1. Prevalent Cases of Alopecia Areata in EU4 and the UK
8.5.2. Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK
8.5.3. Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK
8.5.4. Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK
8.5.5. Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK
8.6. Japan
8.6.1. Prevalent Cases of Alopecia Areata in Japan
8.6.2. Diagnosed Prevalent Cases of Alopecia Areata in Japan
8.6.3. Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan
8.6.4. Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in Japan
8.6.5. Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan
9. Patient Journey
10. Marketed Therapies
10.1. Competitive Landscape: Marketed Drugs
10.2. Baricitinib (OLUMIANT): Eli Lilly and Company/Incyte Corporation
10.2.1. Product Description
10.2.2. Regulatory Milestone
10.2.3. Other Developmental Activities
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.3. Ritlecitinib (LITFULO): Pfizer
10.3.1. Product Description
10.3.2. Regulatory Milestone
10.3.3. Other developmental activities
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.4. Deuruxolitinib (LEQSELVI): Sun Pharmaceuticals
10.4.1. Product Description
10.4.2. Regulatory Milestone
10.4.3. Other Developmental Activities
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
To be continued in the report.
11. Emerging Drug Profiles
11.1. Competitive Landscape: Emerging Drugs
11.2. STS-01: Soterios
11.2.1. Drug Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Trials Information
11.2.4. Safety and Efficacy
11.3. Upadacitinib (RINVOQ): AbbVie
11.3.1. Drug Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Trials Information
11.4. Coacillium (LH-8): Legacy Healthcare
11.4.1. Drug Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Trials Information
11.4.4. Safety and Efficacy
11.5. Bempikibart (ADX-914): Q32 Bio
11.5.1. Drug Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Trials Information
11.5.4. Safety and Efficacy
11.6. Rezpegaldesleukin (NKTR-358): Nektar therapeutics
11.6.1. Drug Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Trials Information
To be continued in the report.
12. Alopecia Areata- 7MM Market Analysis
12.1. Key Findings
12.2. Key Market Forecast Assumptions
12.2.1. Cost Assumptions and Rebates
12.2.2. Pricing Trends
12.2.3. Analogue Assessment
12.2.4. Launch Year and Therapy Uptake
12.3. Market Outlook
12.4. Attribute Analysis
12.5. Total Market Size of Alopecia Areata in the 7MM
12.6. Market Size of Alopecia Areata by Therapies in the 7MM
12.7. Market Size of Alopecia Areata in the United States
12.7.1. Total Market Size of Alopecia Areata
12.7.2. Market Size of Alopecia Areata by Therapies in the United States
12.8. Market Size of Alopecia Areata in EU4 and the UK
12.8.1. Total Market Size of Alopecia Areata
12.8.2. Market Size of Alopecia Areata by Therapies in EU4 and the UK
12.9. Market Size of Alopecia Areata in Japan
12.9.1. Total Market Size of Alopecia Areata
12.9.2. Market Size of Alopecia Areata by Therapies in Japan
13. Key Opinion Leaders' Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
16.1. The United States
16.1.1. Center for Medicare and Medicaid Services (CMS)
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. The United Kingdom
16.3. Japan
16.3.1. MHLW
17. Appendix
17.1. Acronyms and Abbreviations
17.2. Bibliography
17.3. Report Methodology
18. Analyst's Capabilities
19. Disclaimer
20. About the Publisher
List of Tables
Table 1: Summary of Alopecia Areata Epidemiology and Market (2022-2036)
Table 2: Key Events for Alopecia Areata
Table 3: Clinical Manifestations of Alopecia Areata Variants
Table 4: Gene Variants-associated With Alopecia Areata
Table 5: Characteristic Dermatoscopic Findings in Alopecia Areata
Table 6: SALT Scale of Severity and Prognosis
Table 7: Differential Diagnosis
Table 8: Differential Diagnosis of Patchy and Diffuse Alopecia Areata Grouped by Children/ Adolescents and Adults
Table 9: Common Comorbidities in Alopecia Areata
Table 10: Treatment Recommendations for Alopecia Areata
Table 11: Diagnosed Prevalent Cases of Alopecia Areata in the 7MM, in 000's (2022-2036)
Table 12: Prevalent Cases of Alopecia Areata in the US, in 000's (2022-2036)
Table 13: Diagnosed Prevalent Cases of Alopecia Areata in the US, in 000's (2022-2036)
Table 14: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in the US, 000's (2022-2036)
Table 15: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in the US, 000's (2022-2036)
Table 16: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in the US, 000's (2022-2036)
Table 17: Prevalent Cases of Alopecia Areata in EU4 and the UK, 000's (2022-2036)
Table 18: Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK, in 000's (2022-2036)
Table 19: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK, in 000's (2022-2036)
Table 20: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK, in 000's (2022-2036)
Table 21: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK, in 000's (2022-2036)
Table 22: Prevalent Cases of Alopecia Areata in the Japan, in 000's (2022-2036)
Table 23: Diagnosed Prevalent Cases of Alopecia Areata in Japan, in 000's (2022-2036)
Table 24: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan, in 000's (2022-2036)
Table 25: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in Japan, in 000's (2022-2036)
Table 26: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan, in 000's (2022-2036)
Table 27: Key Cross of Marketed Drugs
Table 28: OLUMIANT, Clinical Trials Description, 2026
Table 29: LITFULO, Clinical Trials Description, 2026
Table 30: LEQSELVI, Clinical Trials Description, 2026
Table 31: Key Cross of Emerging Drugs
Table 32: STS-01, Clinical Trials Information, 2026
Table 33: RINVOQ (Upadacitinib), Clinical Trials Description, 2026
Table 34: Coacillium (LH-8), Clinical Trials Description, 2026
Table 35: Bempikibart (ADX-914), Clinical Trials Description, 2026
Table 36: Rezpegaldesleukin (NKTR-358), Clinical Trials Description, 2026
Table 37: Key Market Forecast Assumption of Alopecia Areata in the US
Table 38: Key Market Forecast Assumption of Alopecia Areata in EU4 and the UK
Table 39: Key Market Forecast Assumption of Alopecia Areata in Japan
Table 40: Total Market Size of Alopecia Areata in the 7MM, in USD Million (2022-2036)
Table 41: Market Size of Alopecia Areata by Therapies in the 7MM, USD million (2022-2036)
Table 42: Total Market Size of Alopecia Areata in the US, in USD Million (2022-2036)
Table 43: Market Size of Alopecia Areata by Therapies in the US, USD million (2022-2036)
Table 44: Total Market Size of Alopecia Areata in EU4 and the UK, in USD Million (2022-2036)
Table 45: Market Size of Alopecia Areata by Therapies in EU4 and the UK, USD million (2022-2036)
Table 46: Total Market Size of Alopecia Areata in Japan, in USD million (2022-2036)
Table 47: Market Size of Alopecia Areata by Therapies in Japan, USD million (2022-2036)
List of Figures
Figure 1: Clinical Variants of Alopecia Areata
Figure 2: Nail Abnormalities-associated With Alopecia Areata
Figure 3: Risk Factors for Alopecia Areata
Figure 4: Histopathologic Features of Alopecia Areata
Figure 5: Treatment of Alopecia Areata
Figure 6: Treatment Algorithm
Figure 7: Diagnosed Prevalent Cases of Alopecia Areata in the 7MM (2022-2036)
Figure 8: Prevalent Cases of Alopecia Areata in the US (2022-2036)
Figure 9: Diagnosed Prevalent Cases of Alopecia Areata in the US (2022-2036)
Figure 10: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in the US (2022-2036)
Figure 11: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in the US (2022-2036)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in the US (2022-2036)
Figure 13: Prevalent Cases of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 14: Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 15: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 16: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 17: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 18: Prevalent Cases of Alopecia Areata in the Japan (2022-2036)
Figure 19: Diagnosed Prevalent Cases of Alopecia Areata in Japan (2022-2036)
Figure 20: Gender-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan (2022-2036)
Figure 21: Age Onset-based Diagnosed Prevalent Cases of Alopecia Areata in Japan (2022-2036)
Figure 22: Severity-specific Diagnosed Prevalent Cases of Alopecia Areata in Japan (2022-2036)
Figure 23: Patient Journey
Figure 24: Total Market Size of Alopecia Areata in the 7MM (2022-2036)
Figure 25: Market Size of Alopecia Areata by Therapies in the 7MM (2022-2036)
Figure 26: Total Market Size of Alopecia Areata in the US (2022-2036)
Figure 27: Market Size of Alopecia Areata by Therapies in the US (2022-2036)
Figure 28: Total Market Size of Alopecia Areata in EU4 and the UK (2022-2036)
Figure 29: Market Size of Alopecia Areata by Therapies in EU4 and the UK (2022-2036)
Figure 30: Total Market Size of Alopecia Areata in Japan (2022-2036)
Figure 31: Market Size of Alopecia Areata by Therapies in Japan (2022-2036)
Figure 32: Unmet Needs
Figure 33: SWOT Analysis
Figure 34: HTA
Figure 35: Reimbursement Process in Germany
Figure 36: Reimbursement Process in France
Figure 37: Reimbursement Process in Italy
Figure 38: Reimbursement Process in Spain
Figure 39: Reimbursement Process in the United Kingdom
Figure 40: Reimbursement Process in Japan
A selection of companies mentioned in this report includes, but is not limited to:

• Eli Lilly and Company
• Pfizer
• Incyte Corporation
• Sun Pharmaceuticals

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN17092026004107003653ID1111678046